News

The U.S. Food and Drug Administration (FDA) has designated PUR1900 a Qualified Infectious Disease Product (QIDP) as a potential treatment of fungal infections in the lungs of patients with cystic fibrosis(CF), its developer, Pulmatrix, announced. This  designation accelerates the development of new treatments against infectious agents, and protects the exclusivity of PUR1900 for…

The first patients have been dosed in the Phase 2 clinical trial evaluating NovaBiotics‘ Lynovex (NM001, cysteamine) as an adjunct therapy for infectious exacerbations in cystic fibrosis (CF). CARE-CF (NCT03000348, NBTCS-02) is a randomized, double-blind, parallel group, and placebo-controlled study designed to investigate the optimal dose…

A deeper understanding of how a bacterial enzyme works to degrade the protective layer that surrounds bacteria, helping it to adhere to tissues and to grow and spread, may offer new ways of treating persistent Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF). The study, “Biological function of…

The bacterial species Clostridium difficile is often found in the gut of cystic fibrosis (CF) patients, but rarely makes them ill. In those instances, atypical symptoms can delay diagnosis and proper treatment, and may put patients’ lives in jeopardy, a case study of three people who nearly died of Clostridium difficile…

The emotional impact of an initial Pseudomonas aeruginosa (PA) respiratory infection on cystic fibrosis (CF) patients and those close to them is considerable, and it can lead them to adopt preventive measures that may be ineffectual and intrusive, researchers have found. For the study, “Perception of first respiratory infection…

Blood levels of a protein called sCD40L may serve as a biomarker to track lung complications in patients with cystic fibrosis (CF) infected by Pseudomonas aeruginosa bacteria, according to a new study. Results of the study were reported in the article “A High Level Of Soluble CD40L Is Associated With P. aeruginosa…

First Allied Securities has given the Cystic Fibrosis Foundation a $73,487 donation for research and programs dealing with the disease. Archie Manning, a retired National Football League quarterback, donated memorabilia that First Allied’s charity arm, First Philanthropy, auctioned for some of the donation. In the past seven years, First Philanthropy has…

Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery arm of the Cystic Fibrosis Foundation (CFF), has awarded Aridis Pharmaceuticals a grant to help develop Panaecin (gallium citrate), the company’s development-stage treatment for bacterial lung infections. Panaecin is being evaluated in a Phase 2a clinical trial (GALLIUM-IP-13, NCT02354859) in…

Mortality rates among cystic fibrosis (CF) patients in the United States have significantly decreased during the past decade, but hospitalizations and in-hospital deaths seem to be on the rise, according to the results of a new study. “Contemporary National Trends Of Cystic Fibrosis Hospitalizations And Co-Morbidities In The United States” was…

Hubrecht Organoid Technology (HUB) and the Dutch health insurance companies CZ, Zilveren Kruis and Menzis plan to launch a €3 million ($3.1 million) validation trial to determine whether HUB’s organoid technology can be used to assess how cystic fibrosis (CF) patients might respond to new therapies. HUB’s technology is based…